Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

CMV disease remains the most frequent infectious complication post-transplant and it is associated to high morbidity and even mortality. Global efforts from both transplant physicians and researchers in the field is needed to better characterize the host-virus interactions in the transplant setting, with the aim of decreasing the burden of disease and improve the well-being of patients."HORUS" (Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation) study is a European research project, funded by the European Commission (Horizon Europe) involving 16 partners in seven European countries (France, Spain, Czech Republic, Belgium, Switzerland, Germany and Italy) aiming to better characterize the host-CMV interactions in SOT recipients. The first aim of HORUS study will be to build a European cohort of SOT recipients including clinical characterization and the constitution of a biocollection, which is the aim of HORUS cohort, in order to perform biological, immunological, gene expression, viral kinetics and deep viral genome characterization in the global European HORUS project to improve our understanding of the development of a CMV immune response in the context of immunosuppression.

A cohort 1 of solid-organ transplant recipients at day 0 of transplantation will be included:Consecutive patients meeting the following inclusion criteria will be included:Men and women,Age >= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft,written informed consent obtained from subject,ability to understand and give their written consent,affiliated to health insurance.Exclusion criteria would be:D-R- recipients,participant unable or unwilling to comply with study procedures,subjects who are legally detained in an official institution.A cohort 2 of solid-organ transplant recipients at day 0 of infection:Consecutive patients meeting the following inclusion criteria will be included:Men and women,Age >= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograftwritten informed consent obtained from subject,ability to understand and give their written consent,affiliated to health insurance,post-transplant CMV infection episode.Exclusion criteria would be:D-R- recipients,participant unable or unwilling to comply with study procedures,subjects who are legally detained in an official institution.